Biogen wins U.S. approval of long acting multiple sclerosis drug

August 15, 2014 11:34 PM

9 0

NEW YORK (Reuters) - U.S. health regulators on Friday approved Biogen Idec Inc's Plegridy, a long-acting multiple sclerosis drug that the company expects will eventually replace its older big-selling Avonex treatment.

The company received European approval on July 23 for the drug that is intended to reduce relapses of the debilitating disease and slow its progression.

Read more

To category page